BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29302899)

  • 1. Salivary Duct Carcinoma and Invasive Ductal Carcinoma of the Breast: A Comparative Immunohistochemical Study.
    Jalaly JB; Sanati S; Chernock RD; Dibe DG; El-Mofty SK
    Head Neck Pathol; 2018 Dec; 12(4):488-492. PubMed ID: 29302899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and biomarker analyses of salivary duct carcinomas: comparison with mammary duct carcinoma.
    Hoang MP; Callender DL; Sola Gallego JJ; Huang Z; Sneige N; Luna MA; Batsakis JG; El-Naggar AK
    Int J Oncol; 2001 Oct; 19(4):865-71. PubMed ID: 11562768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of PTEN, Androgen Receptor, HER2/neu, Cytokeratin 5/6, Estrogen Receptor-Beta, HMGA2, and PLAG1 in Salivary Duct Carcinoma.
    Liang L; Williams MD; Bell D
    Head Neck Pathol; 2019 Dec; 13(4):529-534. PubMed ID: 30390196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
    Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
    Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salivary duct carcinoma cytologically diagnosed distinctly from salivary gland carcinomas with squamous differentiation.
    Kawahara A; Harada H; Akiba J; Kage M
    Diagn Cytopathol; 2008 Jul; 36(7):485-93. PubMed ID: 18528886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature.
    Fan CY; Wang J; Barnes EL
    Am J Surg Pathol; 2000 Apr; 24(4):579-86. PubMed ID: 10757407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
    Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N
    Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors.
    Can NT; Lingen MW; Mashek H; McElherne J; Briese R; Fitzpatrick C; van Zante A; Cipriani NA
    Head Neck Pathol; 2018 Mar; 12(1):95-104. PubMed ID: 28681314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma].
    Otsuka K; Imanishi Y; Habu N; Sato Y; Shigetomi S; Fujii R; Sakamoto K; Tomita T; Fujii M; Kameyama K; Ogawa K
    Nihon Jibiinkoka Gakkai Kaiho; 2013 Sep; 116(9):1024-32. PubMed ID: 24191589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological and immunohistochemical behavior of ductal carcinoma of the salivary and lacrimal gland in a Mexican Mestizo population.
    Luna-Ortiz K; Dominguez-Malagon H; Corredor-Alonso GE; Reynoso-Noveron N; Herrera-Ponzanelli C; Luna-Peteuil Z; Zacarias-Ramon LC
    Eur Arch Otorhinolaryngol; 2022 Jan; 279(1):327-333. PubMed ID: 33763743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncocytic intraductal carcinoma of salivary glands: a distinct variant with TRIM33-RET fusions and BRAF V600E mutations.
    Bishop JA; Nakaguro M; Whaley RD; Ogura K; Imai H; Laklouk I; Faquin WC; Sadow PM; Gagan J; Nagao T
    Histopathology; 2021 Sep; 79(3):338-346. PubMed ID: 33135196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
    Udager AM; Chiosea SI
    Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
    Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
    Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma.
    Jeong JS; Cho KJ; Kim D; Lee YS; Song JS
    Pathol Res Pract; 2021 Dec; 228():153678. PubMed ID: 34781210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frankly Invasive Carcinoma Ex-intraductal Carcinoma: Expanding on an Emerging and Perplexing Concept in Salivary Gland Tumor Pathology.
    McLean-Holden AC; Rooper LM; Lubin DJ; Magliocca KR; Manucha V; Sadow PM; Tobias J; Vargo RJ; Thompson LDR; Heidarian A; Weinreb I; Wenig B; Gagan J; Hernandez-Prera JC; Bishop JA
    Head Neck Pathol; 2022 Sep; 16(3):657-669. PubMed ID: 34985683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast.
    Kusafuka K; Kawasaki T; Maeda M; Yamanegi K; Baba S; Ito Y; Inagaki H; Nakajima T
    Histopathology; 2017 Jan; 70(2):164-173. PubMed ID: 27079821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma.
    Kapadia SB; Barnes L
    Mod Pathol; 1998 Nov; 11(11):1033-8. PubMed ID: 9831198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.
    Yang RK; Zhao P; Lu C; Luo J; Hu R
    Hum Pathol; 2019 Feb; 84():173-182. PubMed ID: 30267779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary De novo ductal adenocarcinoma of the lacrimal gland.
    Tripathy D; Agarwal S; Biala A; Rath S; Mittal R
    Ann Diagn Pathol; 2021 Feb; 50():151651. PubMed ID: 33186791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.